A detailed history of Captrust Financial Advisors transactions in Ocugen, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 60,000 shares of OCGN stock, worth $68,400. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,000
Previous 60,000 -0.0%
Holding current value
$68,400
Previous $98,000 5.1%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$0.36 - $0.57 $32 - $51
-90 Reduced 0.15%
60,000 $34,000
Q3 2023

Nov 14, 2023

BUY
$0.4 - $0.62 $16,036 - $24,855
40,090 Added 200.45%
60,090 $24,000
Q2 2023

Aug 14, 2023

BUY
$0.45 - $0.88 $9,000 - $17,600
20,000 New
20,000 $10,000
Q1 2022

May 16, 2022

SELL
$2.34 - $4.72 $2 - $4
-1 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$4.38 - $15.67 $4 - $15
1 New
1 $0
Q2 2021

Aug 16, 2021

SELL
$5.52 - $15.68 $8,280 - $23,520
-1,500 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$1.66 - $15.81 $2,490 - $23,715
1,500 New
1,500 $10,000

Others Institutions Holding OCGN

About Ocugen, Inc.


  • Ticker OCGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,566,000
  • Market Cap $247M
  • Description
  • Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...
More about OCGN
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.